Camena Bioscience appoints Dr Nicola Thompson as Chair of the Board
Cambridge, UK: Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announces it has appointed Dr Nicola Thompson as Chair of its Board of Directors. Following its $10 million Series A financing earlier in the year1, the appointment forms part of the Company’s growth plans to expand commercialisation of its pioneering DNA synthesis…
PlaqueTec recruits first ten patients in BIOPATTERN trial
Cambridge, UK: PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), announces that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema
Cambridgeshire and Nottingham, UK, 28 November 2023: Exonate Ltd., an mRNA therapy company focused on treatments for diabetic complications, announces its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a phase Ib/IIa study.
OBN (UK) Ltd shines a light on outstanding companies within the life sciences industry, at the 2023 OBN Awards, 22 November 2023, London
Abingdon, UK – OBN (UK) Ltd., the not-for-profit membership organisation that catalyses growth for the life sciences industry, is delighted to announce the winners of their 2023 OBN Awards, presented at the Royal Lancaster, London, on Wednesday 22 November.
NanoSyrinx appoints Anthony Johnson as Non-Executive Director
Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy
Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies
CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum, 6th-7th November in London First-in-class ion channel inhibitors show promise as anti-seizure therapeutics fEnhanc3D Genomics expands leadership team with the appointment of Hazel Jones as Chief Operating Officer
Cambridge, UK - Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, announces the appointment of Hazel Jones as Chief Operating Officer.
Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics
Cardiff, UK and Massachusetts, US - Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, and GlobalBio, Inc. (GlobalBio), an antibody engineering company developing methods to engineer improved and more developable therapeutic antibodies, announces they will be extending their collaboration to advance immune checkpoint inhibitors in…
Closed Loop Medicine appoints Konstantinos Vlassis as Chief Technology Officer
London, UK - Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that enable personalized dose optimization, announces that it has appointed Konstantinos Vlassis as Chief Technology Officer (CTO).
Owlstone Medical recruits first patient in phase 2 clinical trial for the early detection of lung cancer through breath biopsy
Cambridge, UK - Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.
Bio-Rad extends range of anti-idiotypic antibodies for use in preclinical and clinical drug development
Range of Highly Selective Anti-Idiotypic Antibodies Now Includes Six Antibodies Specific to Dupilumab and its Biosimilars for Bioanalysis and Drug Monitoring.
FUJIFILM Diosynth Biotechnologies President and CEO Lars Petersen appoints Maja Pedersen as Chief Quality Officer
Hillerød, Denmark – FUJIFILM Diosynth Biotechnologies President and CEO Lars Petersen announces a new strategic leadership appointment to support the company through its next growth phase.
Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies
Dundee, UK: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, announces it is supporting a PhD student in the Institute of Chemical Biology EPSRC Centre for Doctoral Training (CDT) in Chemical Biology, at Imperial College London.
Bio-Rad launches PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers
HERCULES, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announces the launch of its PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers, designed to support PCR applications in basic and translational research, process development, and quality control.
Start Codon invites life sciences leaders, founders and investors to Innovation Showcase 2023
Cambridge, UK - Start Codon, a life science and healthcare venture-building fund, is pleased to invite life sciences leaders, entrepreneurs, and investors from across the life science and biotech industries to attend their Innovation Showcase 2023.
Astrea Bioseparations expands manufacturing and warehousing capacity to support growing demand for its chromatography solutions in North America
Cambridge, UK - Astrea Bioseparations, a leading provider of high-quality bioseparation and purification technologies that help to improve patient outcomes with safer and more effective production of therapeutics, announces the expansion of its manufacturing and warehousing capabilities in the US. The increased capacity reflects growing demand for the Company’s chromatography solutions in North…
Orano Med and Orbit Discovery enter Collaboration to discover novel targeted radioligand therapies for cancer
Texas, US and Oxford, UK - Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 (212Pb) Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit”, a leader in the discovery of therapeutic peptide hits, announce that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells and advance the development…
Bio-Rad Launches First StarBright™ Red Dye and Extends Range of Antibody Markers Conjugated to StarBright Dyes to Enhance Multiplex Flow Cytometry and Research Capabilities
With 29 additional targets the range also includes dog, cow, and pig targets to support translational models in veterinary immunology research.
GADx’s rapid diagnostic test, BotrytisAlert, demonstrates utility across wine production system
Lateral flow test enables Botrytis concentration to be measured in grape must and in finished wine, in addition to monitoring in the vineyard Ten-minute test is simple to use by agronomists and wine growers to address 25% losses in turnover due to BotrUbiquigent appoints Dr Rishi Shah as Head of Chemistry
Appointment brings extensive heterobifunctional and chemical biology expertise in house to drive forward Ubiquigent’s internal DUBTAC drug discovery and DUB-focused partnerships
Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Screening Service
Metrion is now a member of the UK GLP (Good Laboratory Practice) Compliance Monitoring Programme New service with GLP certification further strengthens Metrion’s support for small molecule therapeutics developmentCambridge, UK, 01 August
Global Access Diagnostics (GADx) reintroduces IT-Leish, the rapid diagnostic test for visceral leishmaniasis
London, UK - Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics, announces the launch of IT-Leish, a rapid diagnostic test (RDT) for visceral leishmaniasis (VL).
Gyros Protein Technologies introduces PurePep EasyClean Auto Kit for automated parallel peptide purification
New automated kit overcomes major bottleneck in peptide production, providing optimized simultaneous workflows
NK:IO raises £1.2M, bringing total Seed funding to £5.1M, to advance pioneering NK cell therapy
NK:IO, a leader in natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised £1.2M.